Acquisition of Filovirus Point-of-Care (PoC) Diagnostic Tests
Closed Solicitation Posted
- Solicitation number
- 75A50122Q00005
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- Atlanta, Georgia 30333, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This solicitation from the Department of Health and Human Services seeks quotes to acquire a minimum of 8,500 lateral flow, rapid antigen tests for Ebola virus that are either FDA emergency use authorized or 510(k) cleared, to test oral fluids from cadavers. Quotes are due by January 21, 2022 and must demonstrate the tests can be used on oral fluids from cadavers and have a nine month shelf life from delivery. Award will be made to the responsible offeror with the lowest priced, technically acceptable quote meeting the key requirements.
There is no set-aside designation. The NAICS code is 325413 for in-vitro diagnostic substance manufacturing and the size standard is 1,250 employees. OraSure Technologies is identified as the only current provider that can meet the government's needs. Delivery of the initial lot is required within 60 days of order and the solicitation includes four quantity options to purchase additional lots of the same or improved tests over the next five years. Place of performance is Atlanta, GA.
Notice text
COMBINED SYNOPSIS / SOLICITATION
75A50122Q00005
TITLE: Acquisition of Filovirus Point-of-Care (PoC) Diagnostic Tests
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested.
(ii) The solicitation number is 75A50122Q00005 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; FAR Subpart 13.5—Simplified Procedures for Certain Commercial Items; and FAR Part 12—Acquisition of Commercial Items, and is expected to exceed the simplified acquisition threshold.
(iii) This is a competitive combined synopsis/solicitation. Award(s) will be made to the offerors whose quote(s) successfully address each of the identified requirements, and for which the proposed price is determined to be fair and reasonable.
(iv) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2022-03, with effective date January 1, 2022.
(v) The associated NAICS code 325413 - In-Vitro Diagnostic Substance Manufacturing
and the small business size standard is 1,250 employees. This requirement has no set-aside restrictions.
Files
| File | Type | Posted |
|---|---|---|
| Brand Name Justification_OraSure Test Kits Redacted.pdf | ||
| Combined Synopsis Solicitation_75A50122Q00005.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity